Keros Therapeutics, Inc. (KROS) Dividend History

Company News

• Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Keros’ Director Nominees

  Keros Therapeutics announced that leading independent proxy advisory firm Glass Lewis recommended that Keros stockholders vote 'FOR' all three of the company's director nominees for the upcoming Annual Meeting. Keros stated that the board is best equipped to oversee the strategic review process and execute on the ultimate outcome.

  GlobeNewswire Inc.
• Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price

  Harley-Davidson is exploring strategic alternatives for its financing unit, while Capri Holdings is selling Versace to Prada for $1.375 billion. Several other companies, including Impresoft, Keros Therapeutics, and Rivalry Corp., are also exploring strategic alternatives.

  Benzinga

  Featured Companies: CPRI HOG
• Wall Street Breakfast: The Week Ahead

  Stay updated on Wall Street news with our daily podcast available on Seeking Alpha, iTunes, and Spotify.

  Seeking Alpha

  Featured Companies: ACN ADMA BFH CBUS CRMT DRI EBAY FDS GME IREN KBH KMX KR LEN LZB MAXN MDB NNE NVRI ORA PAL PATH PSTG QGEN SVCO TRUP WMT
• Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable

  Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

  Zacks Investment Research
• Why Shares of Keros Therapeutics Jumped This Week

  The company appointed a new director and an analyst reiterated his position on the stock.

  The Motley Fool

  Featured Companies: BIIB VIR